Skip to main content

    BPEA EQT Pte. Ltd. - Sale of Bushu Pharmaceuticals Ltd. to KKR & Co., Inc.

Leading Japanese law firm Nishimura & Asahi advised BPEA EQT Pte. Ltd., a leading private equity firm, on the sale of all its shares in Bushu Pharmaceuticals Ltd. to KKR & Co., Inc. (NYSE: KKR).

The Nishimura & Asahi team advising BPEA EQT was led by partners Yuki Oi, Kazumaro Kobayashi, Alisa Inuzuka, and counsel Masatsugu Sakamoto.


大井 悠紀

Yuki Oi is a partner in our M&A/Corporate practice group. He advises domestic and international corporations and financial institutions on their cross-border and domestic M&A transactions. He also handles corporate governance matters and general corporate issues, as well as corporate crisis management matters and commercial litigation.
 Some of the major cases he has advised on include representing UFJ Holdings on its integration with Mitsubishi Tokyo Financial Group (2006), Bulldog Sauce on its famous defense against a hostile takeover attempt initiated by Steel Partners (2007), the Osaka Securities Exchange on its integration with the Tokyo Stock Exchange (2011), Idemitsu Kosan on its integration with Showa Shell Sekiyu (2015-19), Toshiba on its divestiture of Toshiba Memory Corporation (2018), and Honda on its strategic alliance with Sony Group in mobility sector (2022).
 He was awarded the Young Lawyer of the Year Award at the ALB Japan Law Awards 2019, and the Innovative Practitioners Award at the FT Innovative Lawyers Awards Asia-Pacific 2020. He was also selected as one of Asia’s top 40 lawyers under 40 by Asian Legal Business in 2017.
 He has also served as a lecturer at the University of Tokyo, Faculty of Law (2012-13), and Graduate Schools for Law and Politics (2014-present).

小林 和真呂

Kazumaro’s antitrust practice spans various industries, including automotive, energy, telecommunication, medical/healthcare and finance. Kazumaro regularly represents clients in high-profile matters, including merger and acquisitions that require approval in multiple jurisdictions, and global and domestic cartel investigations.

犬塚 有理沙

Alisa Inuzuka advises clients in the life science and healthcare industries on matters including pharmaceuticals, medical devices, in vitro diagnostics, cosmetics, health foods, medical systems, and laboratory tests. In addition, she has experience in M&A, regulatory advice, reviewing and drafting various contracts, and crisis management and investigation, as well as communicating with the relevant authorities in these areas. She also supports non-healthcare companies in entering into the healthcare industry as well as the entry of non-Japanese healthcare companies into the Japanese market. She seeks to contribute to enhancing people’s health and lives by working to maximize clients’ business opportunities.

坂元 正嗣

Masatsugu advises domestic and overseas corporate clients on large and small sized M&A transactions and general corporate matters. He has also expanded his practice into M&A transactions involving medical corporations. Prior to joining Nishimura & Asahi, he worked for over three years at a small law firm on a broad range of civil cases, including loans and debt collections, real property transactions, traffic accidents, labor issues, bankruptcies and rehabilitations, litigation and mediation, and criminal cases. He studied at a U.S. law school and trained at a law firm in the U.S. before being seconded to the M&A promotion office of a Japanese company for two years, supporting its M&A activities as part of a principal team. Backed by his diversified work experience, he advises clients in Japanese and English, covering a wide range of inquiries and requests closely meeting the client’s needs.